Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17080992 | 0.69 | — | — | |
| SCHEMBL28242034 | 0.64 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL160279 | 0.63 | CA12 (0.32) | — | |
| SCHEMBL28174101 | 0.63 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL30219628 | 0.62 | NNMT (0.41) | ALDH1A1 | |
| SCHEMBL28986310 | 0.62 | NNMT (0.41) | ALDH1A1 | |
| SCHEMBL19074944 | 0.61 | HRH3 (0.34) | — | |
| SCHEMBL13941528 | 0.60 | — | — | |
| SCHEMBL30555488 | 0.59 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL27141748 | 0.59 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395339-A1 | GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS | VEGENICS PTY LIMITED (AU) | 2021-12-23 | — | — | US | disclosed |
| US-20180118804-A1 | GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS | VEGENICS PTY LIMITED (AU) | 2018-05-03 | — | — | US | disclosed |
| US-9896499-B2 | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis | VEGENICS PTY LIMITED (AU) | 2018-02-20 | — | — | US | disclosed |
| US-20150218249-A1 | GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS | LICENTIA LTD. (FI) | 2015-08-06 | — | — | US | disclosed |
| US-9073997-B2 | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis | VEGENICS PTY LIMITED (AU) | 2015-07-07 | — | — | US | disclosed |
| EP-2125895-B1 | VEGF RECEPTOR ANTAGONISTS FOR TREATING ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS | VEGENICS PTY LTD (AU) | 2015-04-08 | — | — | EP | disclosed |
| US-7875616-B2 | using 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or imatinib; type I and type II diabetes | HAEGERKVIST ROBERT PER | 2011-01-25 | — | — | US | disclosed |
| EP-2125895-A2 | VEGF RECEPTOR ANTAGONISTS FOR TREATING ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS | Vegenics Limited (AU) | 2009-12-02 | — | — | EP | disclosed |
| US-20080267956-A1 | Using vascular endothelial growth factor C specific immunoglobulin as therapeutic which induces tolerance and/or inhibition rejection of cell, tissue or organ transplants | VEGENICS LIMITED (AU) | 2008-10-30 | — | — | US | disclosed |
| US-20080234285-A1 | Combination of Organic Compounds | FELDMAN DAVID LOUIS | 2008-09-25 | — | — | US | disclosed |
| US-20070072932-A1 | Use of tyrosine kinase inhibitor to treat diabetes | HAEGERKVIST ROBERT P | 2007-03-29 | — | — | US | disclosed |
| WO-2006124544-A2 | USE OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| EP-1708691-A1 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006041976-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| EP-1631291-A2 | USE OF TYROSINE KINASE INHIBITORS TO TREAT DIABETES | Hägerkvist, Robert P. (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005070432-A1 | USE OF PDGF-R TK INHIBITORS FOR THE TREATMENT OF MYOCARDITIS AND ITS COMPLICATIONS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070406-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2004105763-A2 | USE OF TYROSINE KINASE INHIBITOR TO TREAT DIABETES | HAEGERKVIST ROBERT PER (SE) | 2004-12-09 | — | — | WO | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2001079144-A2 | FYN KINASE AS A TARGET FOR MODULATION OF INTEGRIN MEDIATED SIGNAL TRANSDUCTION | COR THERAPEUTICS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | ALDH1A1 589/4885 |
| US-20080234285-A1 | Combination of Organic Compounds | REN, PDGFRB, PDGFRA | ALDH1A1 457/4885 |
| US-20070072932-A1 | Use of tyrosine kinase inhibitor to treat diabetes | ABL2, PDGFRA, ABL1 | ALDH1A1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.